---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Ibrutinib - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/ibrutinib
version: v1
---

# Ibrutinib - NCI

# Ibrutinib

Placeholder slot

(i-BROO-tih-nib)

This page contains brief information about ibrutinib
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Imbruvica

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44&audience=consumer)

## Use in Cancer

Ibrutinib
is approved
to treat adults with:

- **[Chronic lymphocytic leukemia](/Common/PopUps/popDefinition.aspx?id=44846&version=Patient&language=English)** and **[small lymphocytic lymphoma](/Common/PopUps/popDefinition.aspx?id=407751&version=Patient&language=English)**.
- **[Chronic lymphocytic leukemia](/Common/PopUps/popDefinition.aspx?id=44846&version=Patient&language=English)** and **[small lymphocytic lymphoma](/Common/PopUps/popDefinition.aspx?id=407751&version=Patient&language=English)** that has a chromosome change called [17p deletion](/Common/PopUps/popDefinition.aspx?id=810645&version=Patient&language=English).
- **[Waldenstr√∂m macroglobulinemia](/Common/PopUps/popDefinition.aspx?id=44854&version=Patient&language=English)** (a type of [non-Hodgkin lymphoma](/Common/PopUps/popDefinition.aspx?id=45148&version=Patient&language=English)).

Ibrutinib
is also being studied in the treatment of other types of
cancer and other conditions.

## More About Ibrutinib

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/638648) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Ibrutinib](https://medlineplus.gov/druginfo/meds/a614007.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?](https://www.cancer.gov/news-events/cancer-currents-blog/2022/kras-targeted-drugs-as-immunotherapy)

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Ibrutinib](https://www.cancer.gov/research/participate/clinical-trials/intervention/C81934) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
